protein tyrosine phosphatase non-receptor type 3Genealiases: PTP-H1 · PTPH1
Q-omics provides the consensus-scored PTPN3 profile across patient tissues and cancer cell-line models. PTPN3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PTPN3 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, PTPN3 RNA expression shows 19,754 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where PTPN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN3 survival associations across molecular data types. PTPN3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN3 RNA expression–survival associations across cancer types. High PTPN3 expression shows unfavorable associations in UCS, ACC, HNSC and BRCA, but favorable associations in KIRC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PTPN3 RNA expression.
This table summarizes PTPN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN3 shows lower tumor expression in KIRC and THCA and higher tumor expression in BLCA, STAD, LUSC and UCEC. The KIRC box plot shows higher PTPN3 RNA expression in normal versus tumor tissue (log2 FC = −1.587, t-test p < 0.001).
This table shows molecular features associated with PTPN3 in patient tissues and cancer cell lines. In patient samples, PTPN3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
